MMDWF (Mind Medicine) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Mind Medicine LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Mind Medicine's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.07.

Mind Medicine's long-term debt to total assets ratio declined from Dec. 2023 (0.11) to Dec. 2024 (0.07). It may suggest that Mind Medicine is progressively becoming less dependent on debt to grow their business.

Mind Medicine LT-Debt-to-Total-Asset Historical Data

The historical data trend for Mind Medicine's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mind Medicine LT-Debt-to-Total-Asset Chart

Mind Medicine Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

0.11

0.07

Mind Medicine Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.11	0.05	0.09	0.08	0.07

Mind Medicine LT-Debt-to-Total-Asset Calculation

Mind Medicine's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	21.854	/	302.151
	=

Mind Medicine's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	21.854	/	302.151
	=

Mind Medicine (OTCPK:MMDWF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Mind Medicine LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Mind Medicine's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Mind Medicine Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mind Medicine Inc (OTCPK:MMDWF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MNMD:USA MMQ:Germany

Address

One World Trade Center, Suite 8500, New York, NY, USA, 10007

Website

https://www.mindmed.co

Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).